| Autor: |
Lehmann-Che, Jacqueline, Hamy, Anne-Sophie, Porcher, Raphaël, Barritault, Marc, Bouhidel, Fatiha, Habuellelah, Hanadi, Leman-Detours, Solenne, Roquancourt, Anne de, Cahen-Doidy, Laurence, Bourstyn, Edwige, Cremoux, Patricia de, Bazelaire, Cedric de, Albiter, Marcela, Giacchetti, Sylvie, Cuvier, Caroline, Janin, Anne, Espié, Marc, Thé, Hugues de, Bertheau, Philippe |
| Předmět: |
|
| Zdroj: |
Breast Cancer Research; 2013, Vol. 15 Issue 3, p1-11, 11p, 1 Color Photograph, 2 Diagrams, 4 Charts, 2 Graphs |
| Abstrakt: |
Introduction: Molecular apocrine (MA) tumors are estrogen receptor (ER) negative breast cancers characterized by androgen receptor (AR) expression. We analyzed a group of 58 transcriptionally defined MA tumors and proposed a new tool to identify these tumors. Methods: We performed quantitative reverse transcription PCR (qRT-PCR) for ESR1, AR, FOXA1 and AR-related genes, and immunohistochemistry (IHC) for ER, PR, Human Epidermal Growth Factor Receptor 2 (HER2), CK5/6, CK17, EGFR, Ki67, AR, FOXA1 and GCDFP15 and we analyzed clinical features. Results: MA tumors were all characterized by ESR1(-) AR(+) FOXA1(+) and AR-related genes positive mRNA profile. IHC staining on these tumors showed 93% ER(-), only 58% AR(+) and 90% FOXA1(+). 67% and 57% MA tumors were HER2(3+) and GCDFP15(+), respectively. Almost all MA tumors (94%) had the IHC signature HER2(3+) or GCDFP15(+) but none of the 13 control basal-like (BL) tumors did. Clinically, MA tumors were rather aggressive, with poor prognostic factors. Conclusion: MA tumors could be better defined by their qRT-PCR-AR profile than by AR IHC. In addition, we found that HER2 or GCDFP15 protein overexpression is a sensitive and specific tool to differentiate MA from BL in the context of ER negative tumors. A composite molecular and IHC signature could, therefore, help to identify MA tumors in daily practice. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink